AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25709054 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Progression (LP)
Number of subjects: 26
Study 25709054 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Progression (DUP)
Number of subjects: 26
Study 25709054 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 26
Study 25601214 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate GSD intervention (n=134)
Number of subjects: 200
Study 25601214 — intervention group
Group type: COMPARATOR
Intervention: Control group (18-months delayed GSD, n=66)
Number of subjects: 200
Study 25601214 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate GSD intervention (women)
Number of subjects: 200
Study 25601214 — intervention group
Group type: COMPARATOR
Intervention: Control group (women)
Number of subjects: 200
Study 25601214 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate GSD intervention (men)
Number of subjects: 200
Study 25601214 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 200
Study 23588309 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin once daily for 7 days
Number of subjects: 12
Study 23588309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20367136 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT) after failing R-CHOP
Number of subjects: 185
Study 20367136 — intervention group
Group type: COMPARATOR
Intervention: Autologous stem cell transplant (ASCT) after failing CHOP
Number of subjects: 185
Study 18720267 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BMP)
Number of subjects: 56
Study 18720267 — intervention group
Group type: COMPARATOR
Intervention: Methadone (MMP)
Number of subjects: 56
Study 16841662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking collateral blood therapy (PCBT) combined with massage therapy
Number of subjects: 60
Study 16841662 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy alone
Number of subjects: 60
Study 16841662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCBT + massage and massage alone)
Number of subjects: 60
Study 12434720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous argatroban infused at a rate of 1.25 micrograms/kg/min for 100 hours
Number of subjects: 12
Study 12434720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 7.5-mg dose of warfarin
Number of subjects: 12
Study 12434720 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban administered alone
Number of subjects: 12
Study 12434720 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of argatroban and warfarin
Number of subjects: 12
Study 12434720 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban administered alone or with warfarin
Number of subjects: 12
Study 9707362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over 3 days)
Number of subjects: 721
Study 9707362 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg per 8 hourly for 5 days)
Number of subjects: 721
Study 8523286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm self-sealing incision (Group A)
Number of subjects: 60
Study 8523286 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm self-sealing incision (Group B)
Number of subjects: 60
Study 8523286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mm incision with one radial suture (Group C)
Number of subjects: 60
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife conization with Sturmdorf sutures
Number of subjects: 183
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife conization without sutures
Number of subjects: 183
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 183
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone height of 20 mm or less
Number of subjects: 183
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone height greater than 20 mm
Number of subjects: 183
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush sampling
Number of subjects: 183
Study 2234708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab sampling
Number of subjects: 183
Study 368538 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of prazosin
Number of subjects: 16
Study 368538 — intervention group
Group type: COMPARATOR
Intervention: 75 mg of hydrallazine
Number of subjects: 16
Study 29734840 — intervention group
Group type: EXPERIMENTAL
Intervention: EnhanceFitness (EF) program, 1-hour session held three times a week for at least 4 months, continued for up to 12 months.
Number of subjects: 1295
Study 29023233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with compañeros
Number of subjects: 189
Study 29023233 — intervention group
Group type: COMPARATOR
Intervention: Control without compañeros
Number of subjects: 189
Study 25336239 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c < 6.9%
Number of subjects: 149
Study 25336239 — intervention group
Group type: COMPARATOR
Intervention: HbA1c ≥ 6.9%
Number of subjects: 149
Study 25336239 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 149
Study 24947719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 24947719 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 23010344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (20 mg, single intravenous dose)
Number of subjects: 62
Study 23010344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19200356 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal nurse practitioner (GNP) follow-up
Number of subjects: 175
Study 19200356 — intervention group
Group type: COMPARATOR
Intervention: GP follow-up
Number of subjects: 175
Study 18210987 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15110545 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (first questionnaire, first lesson for 2 hours, second lesson, second questionnaire)
Number of subjects: 1676
Study 15110545 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 1676
Study 15110545 — intervention group
Group type: COMPARATOR
Intervention: Control (questionnaires only)
Number of subjects: 1676
Study 11264625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine gel
Number of subjects: 149
Study 11264625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 9830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing silicon dioxide, aloe vera, and allantoin
Number of subjects: 0
Study 9830646 — intervention group
Group type: COMPARATOR
Intervention: Control gel with silicon dioxide
Number of subjects: 0
Study 9830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel with all 3 active substances
Number of subjects: 0
Study 9830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified crossover design with all subjects from study II
Number of subjects: 0
Study 9830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Study I and Study III results
Number of subjects: 0
Study 7473467 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of disability and pain
Number of subjects: 95
Study 7473467 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain
Number of subjects: 95
Study 7473467 — intervention group
Group type: EXPERIMENTAL
Intervention: Other baseline characteristics
Number of subjects: 95
Study 29568100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1754
Study 29568100 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1754
Study 27034119 — intervention group
Group type: EXPERIMENTAL
Intervention: VA bursts during optimal reperfusion (TIMI 3, stable ST-recovery, and MBG 3)
Number of subjects: 126
Study 27034119 — intervention group
Group type: COMPARATOR
Intervention: No VA bursts during optimal reperfusion (TIMI 3, stable ST-recovery, and MBG 3)
Number of subjects: 126
Study 24768221 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate
Number of subjects: 40
Study 24768221 — intervention group
Group type: COMPARATOR
Intervention: Locking intramedullary nail
Number of subjects: 40
Study 24320801 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 20
Study 24320801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20597872 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transpupillary thermotherapy (TTT)
Number of subjects: 98
Study 20597872 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 98
Study 19332985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery)
Number of subjects: 76
Study 19332985 — intervention group
Group type: COMPARATOR
Intervention: Oral iron protein succinylate (80 mg/day)
Number of subjects: 76
Study 19332985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 76
Study 19332985 — intervention group
Group type: COMPARATOR
Intervention: Oral iron protein succinylate
Number of subjects: 76
Study 16785154 — intervention group
Group type: EXPERIMENTAL
Intervention: CC/hMG/cetrorelix protocol
Number of subjects: 120
Study 16785154 — intervention group
Group type: COMPARATOR
Intervention: buserelin long protocol
Number of subjects: 120
Study 15472846 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation for the treatment of CAP
Number of subjects: 0
Study 15472846 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (external comparison group)
Number of subjects: 0
Study 11041314 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hydrocortisone (100 mg, orally 11 h before)
Number of subjects: 12
Study 11041314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hydrocortisone (20 mg twice a day for 1 week)
Number of subjects: 12
Study 11041314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9309369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg o.d.
Number of subjects: 450
Study 9309369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg b.i.d.
Number of subjects: 450
Study 9309369 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (AMX/CA) 500 mg/125 mg t.i.d.
Number of subjects: 450
Study 8323935 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction program
Number of subjects: 89
Study 8323935 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered anticipatory guidance
Number of subjects: 89
Study 8323935 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 89
Study 8323935 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction
Number of subjects: 89
Study 2939862 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg kg‐1
Number of subjects: 30
Study 2939862 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1.6 mg kg‐1 plus infusion
Number of subjects: 30
Study 31285357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (TC) strategy with adalimumab (40 mg sc)
Number of subjects: 0
Study 31285357 — intervention group
Group type: COMPARATOR
Intervention: Symptom-based clinical management (CM)
Number of subjects: 0
Study 29884605 — intervention group
Group type: EXPERIMENTAL
Intervention: Year-long online lifestyle intervention for weight loss
Number of subjects: 67
Study 27494932 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack Track School app (gamified monitoring app)
Number of subjects: 1400
Study 23875718 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-based patient education programme (group and individual education)
Number of subjects: 141
Study 23875718 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 141
Study 22633843 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based prevention program
Number of subjects: 209
Study 22633843 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 209
Study 20667854 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural cortical stimulation during intensive speech-language therapy
Number of subjects: 8
Study 20667854 — intervention group
Group type: COMPARATOR
Intervention: Intensive speech-language therapy without epidural stimulation (Control)
Number of subjects: 8
Study 20667854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective caregiver ratings (Investigational participants)
Number of subjects: 8
Study 20667854 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional imaging (Investigational participants)
Number of subjects: 8
Study 18317336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric design soft contact lenses (Biomedics 55 Evolution, CooperVision)
Number of subjects: 20
Study 18317336 — intervention group
Group type: COMPARATOR
Intervention: Spherical design soft contact lenses (Biomedics 55, CooperVision)
Number of subjects: 20
Study 18317336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lens designs (aspheric and spherical)
Number of subjects: 20
Study 16032618 — intervention group
Group type: EXPERIMENTAL
Intervention: Social services intervention
Number of subjects: 84
Study 11853795 — intervention group
Group type: EXPERIMENTAL
Intervention: STI571
Number of subjects: 8
Study 11853795 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 8
Study 10027447 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n = 31) with targeted oxygen delivery index (DO2I) value of > 600 mL/min/m2
Number of subjects: 63
Study 10027447 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32) with conventional therapy and normal targeted oxygen delivery
Number of subjects: 63
Study 10027447 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n = 31)
Number of subjects: 63
Study 10027447 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 63
Study 10027447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 7670005 — intervention group
Group type: EXPERIMENTAL
Intervention: DBM/Ara-C/Cy conditioning
Number of subjects: 11
Study 7670005 — intervention group
Group type: COMPARATOR
Intervention: TBI/Cy conditioning
Number of subjects: 11
Study 1675225 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (bolus injection)
Number of subjects: 0
Study 1675225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6185041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per body weight every eight hours for 14 days (Group I)
Number of subjects: 50
Study 6185041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine adjusted to body surface area based on an adult dose of 500 mg base eight hourly for 14 days (Group II)
Number of subjects: 50
Study 6185041 — intervention group
Group type: COMPARATOR
Intervention: Both groups treated with quinine
Number of subjects: 50
Study 30680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-type RT (3 sets of 6-8 RM with 3-min rest)
Number of subjects: 25
Study 30680448 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-type RT (3 sets of 20-25 RM with 60-s rest)
Number of subjects: 25
Study 30680448 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 25
Study 28449320 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Number of subjects: 213
Study 28449320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 25983022 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-14
Number of subjects: 93
Study 25983022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 24630956 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon-bone (QTB) graft
Number of subjects: 51
Study 24630956 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 51
Study 22943931 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 (up to 180 mg)
Number of subjects: 0
Study 19953987 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Number of subjects: 82
Study 19953987 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study 17575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous responding with targets separated by less than 60 degrees of spatial angle
Number of subjects: 0
Study 17575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete responding with targets separated by greater than 60 degrees of spatial angle
Number of subjects: 0
Study 17575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants allowed to correct movements after initiation
Number of subjects: 0
Study 17575340 — intervention group
Group type: COMPARATOR
Intervention: Standard task without corrections
Number of subjects: 0
Study 15323576 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine 4mg
Number of subjects: 428
Study 15323576 — intervention group
Group type: COMPARATOR
Intervention: Intermittent subcutaneous apomorphine injections
Number of subjects: 428
Study 15323576 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous apomorphine infusions
Number of subjects: 428
Study 15323576 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine challenge test
Number of subjects: 428
Study 15323576 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 428
Study 11731749 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 0.5 g.kg‐1 as bolus at the start of skin incision, and postoperatively 0.5 g.kg‐1 daily three times a day for 3 days (72 hrs)
Number of subjects: 30
Study 11731749 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 0.25 g.kg‐1 as bolus at the start of skin incision plus 3% HTS, 20 ml.h‐1 intraoperatively and mannitol 0.25 g.kg‐1 daily three times a day for 3 days plus HTS in the concentration of 3% in the first day and 2% and 1% the second and the third day after surgery
Number of subjects: 30
Study 11731749 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% HTS 3.5 ml kg‐1 as bolus at the start of skin incision plus 3% HTS, 20 ml hr‐1 intraoperatively and 3% HTS, 20 ml h‐1 on the first day and 2% and 1% the second and the third day after surgery
Number of subjects: 30
Study 11731749 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 0.5 g.kg‐1 and Mannitol 0.25 g.kg‐1
Number of subjects: 30
Study 11731749 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% HTS
Number of subjects: 30
Study 11731749 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 11731749 — intervention group
Group type: COMPARATOR
Intervention: Groups M and MH
Number of subjects: 30
Study 11731749 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H
Number of subjects: 30
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective group (passing the 12 mm barium pill test)
Number of subjects: 23
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective group (alleviation of dysphagia)
Number of subjects: 23
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective group (Part 2)
Number of subjects: 23
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective group (long-term follow-up)
Number of subjects: 23
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill test (overall correlation)
Number of subjects: 23
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Passing the pill test 1 week after dilation
Number of subjects: 23
Study 9165314 — intervention group
Group type: EXPERIMENTAL
Intervention: Failing the pill test
Number of subjects: 23
Study 7965438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor metabolites
Number of subjects: 39
Study 7965438 — intervention group
Group type: COMPARATOR
Intervention: Immediate hypersensitivity reactions
Number of subjects: 39
Study 7965438 — intervention group
Group type: COMPARATOR
Intervention: Nonaffected control subjects
Number of subjects: 39
Study 3593990 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (6 months of cyclophosphamide, adriamycin, and fluorouracil followed by 6 months of cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone)
Number of subjects: 41
Study 3593990 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (12 months of CMFVP)
Number of subjects: 41
Study 3593990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens with tamoxifen 20 mg bid for patients with positive estrogen receptor status
Number of subjects: 41
Study 28072667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein visualization device (S)
Number of subjects: 129
Study 28072667 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 129
Study 28104469 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention consisting of weekly health education and 3 moderate-to-vigorous physical activity sessions/week
Number of subjects: 160
Study 28104469 — intervention group
Group type: COMPARATOR
Intervention: Control condition receiving health information and laboratory testing results
Number of subjects: 160
Study 26206644 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 100
Study 26206644 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo injection)
Number of subjects: 100
Study 23797771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (CT)
Number of subjects: 427
Study 23797771 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 427
Study 23797771 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (C)
Number of subjects: 427
Study 21192148 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive family presence
Number of subjects: 50
Study 21192148 — intervention group
Group type: COMPARATOR
Intervention: No supportive family presence
Number of subjects: 50
Study 19436693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg daily
Number of subjects: 6800